Tonix Pharmaceuticals Holding Future Growth
Future criteria checks 2/6
Tonix Pharmaceuticals Holding is forecast to grow earnings and revenue by 11.5% and 75.6% per annum respectively while EPS is expected to grow by 62.7% per annum.
Key information
11.5%
Earnings growth rate
62.7%
EPS growth rate
Biotechs earnings growth | 42.4% |
Revenue growth rate | 75.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 01 Aug 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 22 | -93 | N/A | N/A | 2 |
12/31/2024 | 14 | -89 | N/A | N/A | 3 |
12/31/2023 | 6 | -110 | N/A | N/A | 3 |
3/31/2023 | N/A | -123 | -132 | -100 | N/A |
12/31/2022 | N/A | -117 | -146 | -98 | N/A |
9/30/2022 | N/A | -112 | -167 | -98 | N/A |
6/30/2022 | N/A | -102 | -156 | -88 | N/A |
3/31/2022 | N/A | -98 | -141 | -86 | N/A |
12/31/2021 | N/A | -92 | -111 | -76 | N/A |
9/30/2021 | N/A | -80 | -81 | -67 | N/A |
6/30/2021 | N/A | -73 | -80 | -69 | N/A |
3/31/2021 | N/A | -64 | -69 | -60 | N/A |
12/31/2020 | N/A | -52 | -57 | -49 | N/A |
9/30/2020 | N/A | -46 | -45 | -41 | N/A |
6/30/2020 | N/A | -42 | -33 | -33 | N/A |
3/31/2020 | N/A | -34 | -27 | -27 | N/A |
12/31/2019 | N/A | -31 | -27 | -27 | N/A |
9/30/2019 | N/A | -31 | -27 | -27 | N/A |
6/30/2019 | N/A | -28 | -25 | -25 | N/A |
3/31/2019 | N/A | -29 | -26 | -26 | N/A |
12/31/2018 | N/A | -29 | -24 | -24 | N/A |
9/30/2018 | N/A | -24 | -22 | -22 | N/A |
6/30/2018 | N/A | -24 | -22 | -22 | N/A |
3/31/2018 | N/A | -23 | -21 | -21 | N/A |
12/31/2017 | N/A | -21 | -19 | -19 | N/A |
9/30/2017 | N/A | -23 | -20 | -20 | N/A |
6/30/2017 | N/A | -25 | -23 | -23 | N/A |
3/31/2017 | N/A | -30 | -27 | -27 | N/A |
12/31/2016 | N/A | -39 | N/A | -37 | N/A |
9/30/2016 | N/A | -45 | N/A | -44 | N/A |
6/30/2016 | N/A | -50 | N/A | -48 | N/A |
3/31/2016 | N/A | -52 | N/A | -49 | N/A |
12/31/2015 | N/A | -48 | N/A | -43 | N/A |
9/30/2015 | N/A | -44 | N/A | -39 | N/A |
6/30/2015 | N/A | -38 | N/A | -31 | N/A |
3/31/2015 | N/A | -32 | N/A | -28 | N/A |
12/31/2014 | N/A | -28 | N/A | -23 | N/A |
9/30/2014 | N/A | -22 | N/A | -18 | N/A |
6/30/2014 | N/A | -18 | N/A | -16 | N/A |
3/31/2014 | N/A | -14 | N/A | -11 | N/A |
12/31/2013 | N/A | -11 | N/A | -9 | N/A |
9/30/2013 | N/A | -10 | N/A | -6 | N/A |
6/30/2013 | N/A | -8 | N/A | -5 | N/A |
3/31/2013 | N/A | -9 | N/A | -5 | N/A |
12/31/2012 | N/A | -9 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TPM0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TPM0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TPM0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TPM0's revenue (75.6% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: TPM0's revenue (75.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TPM0's Return on Equity is forecast to be high in 3 years time